Evidence map›Paper›PMID 36840551›Full record

ArticleApplied and environmental microbiology2023

Capacity of a Microbial Synbiotic To Rescue the

Braden T Tierney, Pieter Van den Abbeele, Gabriel A Al-Ghalith, Lynn Verstrepen, Jonas Ghyselinck, Marta Calatayud, Massimo Marzorati, Azza A Gadir, Brendan Daisley, Gregor Reid and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Applied and environmental microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Veterinary sciences · 2026
    Article
  5. Article
  6. Gut microbes · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Braden T Tierney *Seed Health, Los Angeles, California, USA.
Pieter Van den Abbeele *ProDigest BV, Ghent, Belgium.
Gabriel A Al-GhalithSeed Health, Los Angeles, California, USA.
Lynn VerstrepenProDigest BV, Ghent, Belgium.
Jonas GhyselinckProDigest BV, Ghent, Belgium.
Marta CalatayudProDigest BV, Ghent, Belgium.
Massimo MarzoratiProDigest BV, Ghent, Belgium.
Azza A GadirSeed Health, Los Angeles, California, USA.
Brendan DaisleySeed Health, Los Angeles, California, USA.
Gregor ReidThe University of Western Ontario, London, Ontario, Canada.ORCID 0000-0001-9658-5696
Peter A BronSeed Health, Los Angeles, California, USA.
Dirk GeversSeed Health, Los Angeles, California, USA.
Raja DhirSeed Health, Los Angeles, California, USA.
Sheri L SimmonsSeed Health, Los Angeles, California, USA.ORCID 0000-0001-7046-8862
ProDigest (Belgium) · BEWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human gut microbiome contributes crucial bioactive metabolites that support human health and is sensitive to perturbations from the ingestion of alcohol and antibiotics. We interrogated the response and recovery of human gut microbes after acute alcohol or broad-spectrum antibiotic administration in a gut model simulating the luminal and mucosal colonic environment with an inoculated human microbiome. Both alcohol and antibiotic treatments reduced the production of major short-chain fatty acids (SCFAs) (acetate, propionate, and butyrate), which are established modulators of human health. Treatment with a microbial synbiotic restored and enhanced gut function. Butyrate and acetate production increased by up to 29.7% and 18.6%, respectively, relative to untreated, dysbiotic samples. In parallel, treatment led to increases in the relative abundances of beneficial commensal organisms not found in the synbiotic (e.g., Faecalibacterium prausnitzii and the urolithin-producing organism Gordonibacter pamelaeae) as well as species present in the synbiotic (e.g., Bifidobacterium infantis), suggesting synergistic interactions between supplemented and native microorganisms. These results lead us to conclude that functional shifts in the microbiome, evaluated by both metabolite production and specific taxonomic compositional changes, are an appropriate metric to assess microbiome "recovery" following a dysbiosis-inducing disruption. Overall, these findings support the execution of randomized clinical studies to determine whether a microbial synbiotic can help restore microbiome function after a disruption.

Indexed as

Gastrointestinal MicrobiomeSynbioticsAnti-Bacterial AgentsButyratesEthanolFatty Acids, VolatileHumansAnti-Bacterial AgentsButyratesEthanolFatty Acids, Volatilecross-feedinggut microbiomemetabolomicsmicrobial interventionshallow shotgun sequencingshort-chain fatty acid

Identifiers

PMID36840551
PMCPMC10056957
OpenAlexW4321495254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.